The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2013
Drug resistance among new smear-positive pulmonary tuberculosis cases in Thailand.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kateruttanakul P, Unsematham S
Аннотация
SETTING: A 1200-bed hospital in Bangkok, Thailand.
OBJECTIVE: To describe pre-treatment drug susceptibility patterns and determine factors predicting drug resistance in new sputum-smear positive tuberculosis (TB) patients in Thailand.
DESIGN: In a retrospective cohort study from October 2007 to September 2010, clinical data on all new sputum-smear positive pulmonary TB (PTB) patients were reviewed. The pre-treatment drug susceptibility patterns and statistically significant differences in variables between groups of patients were described.
RESULTS: A total of 769 new smear-positive PTB patients were included in the study. Overall rates of pre-treatment isoniazid resistance and multidrug-resistant TB were respectively 11.8% and 2.5%. TB patients co-infected with the human immunodeficiency virus (HIV) had a four times greater risk of pre-treatment drug resistance than non-HIV-infected patients. No other groups of patients that needed to be prioritised for drug susceptibility testing (DST) were identified.
CONCLUSION: Groups of patients to be prioritised for DST other than those with HIV infection could not be identified.
OBJECTIVE: To describe pre-treatment drug susceptibility patterns and determine factors predicting drug resistance in new sputum-smear positive tuberculosis (TB) patients in Thailand.
DESIGN: In a retrospective cohort study from October 2007 to September 2010, clinical data on all new sputum-smear positive pulmonary TB (PTB) patients were reviewed. The pre-treatment drug susceptibility patterns and statistically significant differences in variables between groups of patients were described.
RESULTS: A total of 769 new smear-positive PTB patients were included in the study. Overall rates of pre-treatment isoniazid resistance and multidrug-resistant TB were respectively 11.8% and 2.5%. TB patients co-infected with the human immunodeficiency virus (HIV) had a four times greater risk of pre-treatment drug resistance than non-HIV-infected patients. No other groups of patients that needed to be prioritised for drug susceptibility testing (DST) were identified.
CONCLUSION: Groups of patients to be prioritised for DST other than those with HIV infection could not be identified.